Literature DB >> 3416724

Haemodynamic effects of an antihypertensive diuretic substance on the forearm circulation of patients with essential hypertension.

J A Bouthier1, M E Safar, E Deschamps, T Tarrade.   

Abstract

Vascular resistance, arterial compliance and venous tone of the forearm were determined using plethysmographic and Doppler techniques in patients with sustained essential hypertension before and after administration of a new antihypertensive agent with low diuretic effect, cicletanine. After 1 week of treatment, no significant change in the haemodynamic parameters was observed. After 3 months' treatment, blood pressure and forearm vascular resistance significantly decreased, but arterial diameter and forearm venous tone did not change. The study suggested that the antihypertensive effect of cicletanine involved a pharmacological action of the drug on the arterial smooth muscle of both small and large arteries, independently of the blood pressure reduction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3416724

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  4 in total

1.  A comparison of the acute effects of cicletanine and bendrofluazide on urinary electrolytes and plasma potassium in essential hypertension.

Authors:  D R Singer; N D Markandu; A L Sugden; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Effects of cicletanine on the urinary excretion of prostanoids and kallikrein, and on renal function in man.

Authors:  K Tsunoda; K Abe; K Omata; T Hagino; N Minami; M Munakata; K Yoshida; H Sakuma; S Misawa; S Arima
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

3.  Cicletanine sulfate: inhibition of anion transport systems and natriuretic activity.

Authors:  R P Garay; C Rosati; C Nazaret; A Esanu; T Tarrade; P Braquet
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

4.  Cicletanine does not affect plasma atrial natriuretic peptide concentration in healthy subjects.

Authors:  I Berlin; G Deray; G Maistre; F Masson; C Barthelemy; J C Legrand; C Jacobs
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.